Payment overview · 2025
General Payments
$1,196.61
52 reported records · 22 companies
Healthcare provider profile · identity verified
Tina Marie Galey, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ASTORIA, OR · NPI 1437229366
Verified facts
What the public records show
CMS Open Payments records show Tina Marie Galey, ARNP received $1,196.61 in general payments during 2025 across 52 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $176.03 | 14.7% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $125.10 | 10.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $111.70 | 9.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $106.75 | 8.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $84.24 | 7.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $75.89 | 6.3% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.95 | 4.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.04 | 4.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.37 | 3.7% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $39.34 | 3.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $37.54 | 3.1% | 2 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $33.94 | 2.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.38 | 2.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $29.37 | 2.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.80 | 2.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $26.67 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.38 | 2.2% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $26.36 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.21 | 1.9% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $20.96 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.17 | 1.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17.42 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,096.62 | 51 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $117.68 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $111.70 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $106.75 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $84.24 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.25 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $59.89 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $57.95 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.04 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.38 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $27.80 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 367 | 66 |
| Lisinopril | Lisinopril | 330 | 62 |
| Oxycodone Hcl | Oxycodone Hcl | 234 | 33 |
| Gabapentin | Gabapentin | 218 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 201 | 38 |
| Omeprazole | Omeprazole | 193 | 37 |
| Losartan Potassium | Losartan Potassium | 178 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 141 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 37 |
| Potassium Chloride | Potassium Chloride | 127 | 29 |
| Eliquis | Apixaban | 123 | 21 |
| Pregabalin | Pregabalin | 119 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 24 |
| Trazodone Hcl | Trazodone Hcl | 110 | 20 |
| Furosemide | Furosemide | 109 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 108 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 28 |
| Celecoxib | Celecoxib | 92 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 21 |
| Metformin Hcl | Metformin Hcl | 90 | 20 |
| Metformin Hcl Er | Metformin Hcl | 89 | 19 |
| Buspirone Hcl | Buspirone Hcl | 88 | 15 |
| Sertraline Hcl | Sertraline Hcl | 76 | 17 |
| Carvedilol | Carvedilol | 66 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 14 |
| Jardiance | Empagliflozin | 59 | suppressed |
| Ezetimibe | Ezetimibe | 58 | suppressed |
| Allopurinol | Allopurinol | 56 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 56 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Glimepiride | Glimepiride | 50 | 11 |
| Alprazolam | Alprazolam | 49 | suppressed |
| Levofloxacin | Levofloxacin | 48 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 12 |
| Ibuprofen | Ibuprofen | 36 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 16 |
| Glipizide | Glipizide | 26 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 12 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Mili | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,196.61 · 52 records | AstraZeneca Pharmaceuticals LP | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, AREXVY, ARISTADA, AUSTEDO XR, BREZTRI, CAPLYTA, FANAPT, FARXIGA, Fluad, Flucelvax, GEMTESA, LYBALVI, MOUNJARO, NEXPLANON, QULIPTA, REXULTI, SHINGRIX, SLYND, TMS NeuroHealth Centers Inc., TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZENPEP, ZEPBOUND, ZURZUVAE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error